April 27, 2022
L. Alison McInnes, MD, MS
Beyond the development of new mental health treatments, research is a fundamental influence on payers to increase coverage for therapies – and for politicians who campaign for increased treatment access and reduced stigma. Peer-reviewed articles help unify practice standards so patients receive the best possible care, and ensure that clinicians have the best information to help protect against potential legal challenges.
It’s critical for your clinical practice to stay current with the newest research literature, but it can be hard to keep up. The Evidence Base aims to help clinicians follow the developments that advance evidence-based mental health practices.
Recently, two noteworthy research papers caught our attention at Osmind. The first centers on the safety of ketamine in community practice. The second paper focuses on ketamine drug interactions. Both are summarized below.
While this paper is behind a paywall, it is highly relevant to clinicians and demonstrates the importance of real world evidence. Clinical trials enroll a relatively small number of carefully screened patients. Real world evidence furthers the preliminary understanding gained from clinical trials, to establish the safety and efficacy of treatment interventions in the general population.
The Gastaldon et al. article describes safety/tolerability concerns emerging with esketamine administration in real-world populations. A preliminary analysis of data obtained by the United States Food and Drug Administration Adverse Event Reporting System (FAERS) suggests there are discrepancies in the safety/tolerability profiles of esketamine between clinical trials and real-world care settings.
Int J Neuropsychopharmacol. 2021 Oct 23;24(10):808-831. doi: 10.1093/ijnp/pyab039. PMID: 34170315; PMCID: PMC8538895. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ.
About Dr. Alison McInnes
Dr. Alison McInnes is Vice President, Medical Affairs at Osmind. She is a nationally recognized expert in psychiatry and mood and anxiety disorders, having specialized in treating refractory disease for over a decade. She is an expert in ketamine treatment and psychedelic medicine. McInnes founded and served as Medical Director for Kaiser Permanente's ketamine infusion therapy program for a number of years, and was previously an Associate Professor of Psychiatry at Mount Sinai School of Medicine for 8 years where she ran a lab in psychiatric genetics. She was also an adjunct clinical professor at UCSF.
Dr. McInnes is regularly invited to speak at national and international conferences and consults for biopharmaceutical companies working at the cutting edge of neuropsychiatry. She is a member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) Certification Governance Commission, which is an autonomous governing body that oversees the development, implementation, and management of a certification program for clinicians offering ketamine therapy. In her current clinical practice, she focuses on treatment-resistant mood disorders and complex cases.
Dr. McInnes received Bachelor’s and Master’s degrees from Stanford University and her MD from Columbia University. She completed residency at UCSF and research at the VA Research Fellowship and Howard Hughes Physician Research Fellowship in Psychiatric Genetics at UCSF.
Get the latest in your inbox